BioSpace News Archive

AcelRx Pharmaceuticals, Inc.today announced the publication of real-world data in patients undergoing awake plastic surgery showing a rapid recovery time and minimal side effects with the use of sufentanil sublingual tablet (SST) for pain management.

Butterfly Network, Inc., a digital health company transforming care with handheld, whole-body ultrasound, and Ambra Health, an Intelerad Company, and maker of a leading cloud-based, medical image management suite, announced a partnership to accelerate and simplify interoperability for bedside imaging data.

Eko announced that the Imperial College of London, in conjunction with the UK National Health Service, published a study1 which highlights Eko’s ability to screen patients for heart failure in seconds with AI during physical exams.

Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, is pleased to provide an update on the patient recruitment for the phase III clinical study for the treatment of superficial basal cell carcinoma (sBCC) with Ameluz® photodynamic therapy (Ameluz®-PDT) in combination with the BF-RhodoLED® lamp in the U.S.

ViiV Healthcare today announced that the US Food and Drug Administration (FDA) approved Cabenuva.

ResMed announced the appointment of Urvashi Tyagi as chief technology officer.

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today that it has completed the acquisition of Virex Health, Inc., a Boston, MA based company (“Virex”), spun out of the labs of Professors Mark Grinstaff and Scott Schaus at BU, on February 1, 2022.

Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that it has completed cohort 1 and advanced to cohort 2 in the 64Cu/67Cu SARTATE™ Neuroblastoma trial (CL04 trial).

Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company and Aspen, a South African headquartered multinational pharmaceutical company announced today their partnership to launch Trelstar® (Triptorelin) in South Africa for the treatment of locally advanced and metastatic hormone dependent prostate cancer.

NTx, a bioinformatics and biomanufacturing company advancing cell free, continuous flow manufacturing solutions for medical products and material sciences, today announced that the company has received a grant from the Bill & Melinda Gates Foundation to advance novel solutions for mRNA production and related supply chain challenges.